These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8141718)

  • 1. Repeat thrombolysis.
    Cross D
    Aust N Z J Med; 1993 Dec; 23(6):749-52. PubMed ID: 8141718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?
    Brügemann J; de Graeff PA; van der Meer J; Lie KI
    Drugs Aging; 1995 Aug; 7(2):110-6. PubMed ID: 7579782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous thrombolytic therapy in myocardial infarction: an analytical review.
    Shammas NW; Zeitler R; Fitzpatrick P
    Clin Cardiol; 1993 Apr; 16(4):283-92. PubMed ID: 8458108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
    J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ; Grimm AM; Hopkins LE
    Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.
    Fears R; Ferres H; Glasgow E; Standring R; Hogg KJ; Gemmill JD; Burns JM; Rae AP; Dunn FG; Hillis WS
    Br Heart J; 1992 Aug; 68(2):167-70. PubMed ID: 1389731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet reactivity and streptokinase resistance following antecedent streptokinase therapy for myocardial infarction.
    Gorog DA; Ahmed N; Davies GJ
    Cardiology; 1999; 91(1):56-9. PubMed ID: 10393399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
    Hiatt MD
    Cardiology; 1999; 91(4):243-9. PubMed ID: 10545680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).
    Tatu-Chiţoiu G; Teodorescu C; Dan M; Guran M; Căpraru P; Istrăţescu O; Tatu-Chiţoiu A; Bumbu A; Chioncel V; Arvanitopol S; Dorobanţu M
    Rom J Intern Med; 2004; 42(3):557-73. PubMed ID: 16366130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction.
    Fears R; Hearn J; Standring R; Anderson JL; Marder VJ
    Am Heart J; 1992 Aug; 124(2):305-14. PubMed ID: 1636574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres.
    Lee HS; Yule S; McKenzie A; Cross S; Reid T; Davidson R; Jennings K
    Eur Heart J; 1993 Dec; 14(12):1640-3. PubMed ID: 8131761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolytic therapy in acute myocardial infarction.
    Rutherford JD; Braunwald E
    Chest; 1990 Apr; 97(4 Suppl):136S-145S. PubMed ID: 2108851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction.
    McLeod DC; Coln WG; Thayer CF; Perfetto EM; Hartzema AG
    Ann Pharmacother; 1993; 27(7-8):956-62. PubMed ID: 8364282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralising antibodies after streptokinase treatment for myocardial infarction: a persisting puzzle.
    McGrath K; Hogan C; Hunt D; O'Malley C; Green N; Dauer R; Dalli A
    Br Heart J; 1995 Aug; 74(2):122-3. PubMed ID: 7546988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Side effects of thrombolytic therapy in patients with myocardial infarction].
    Agostoni A; Gardinali M
    Cardiologia; 1995 Dec; 40(12):899-908. PubMed ID: 8901040
    [No Abstract]   [Full Text] [Related]  

  • 18. [Endovenous thrombolysis in acute myocardial infarct. The experience in a community hospital. An analysis of 120 patients].
    Jorge Sdo C
    Arq Bras Cardiol; 1992 Jul; 59(1):23-30. PubMed ID: 1341143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary thrombolysis and previous SK therapy.
    Massel D
    Can J Cardiol; 1993; 9(6):518-20. PubMed ID: 8221347
    [No Abstract]   [Full Text] [Related]  

  • 20. Safe use of thrombolysis in the elderly.
    Wittry MD; Thornton TA; Chaitman BR
    Geriatrics; 1989 Nov; 44(11):28-30, 33-6. PubMed ID: 2509296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.